PIH31 Inconsistency in the Valuations of Euroqol Eq-5d-5l Health States in China was More Related to Interviewer and to Interview Process than to Respondents’ Characteristics  by Yang, Z
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A737
from which only 32 were original research empirical studies (0.3 0/000). Most studies 
were cross-sectional (72%), with only (25%) being prospective. Patient reported out-
comes were the most frequent adherence measures (65%). The Big Five model was 
the most frequent personality explicative framework (71%), followed by self-efficacy 
and beliefs. Conscientiousness was identified as an important adherent personality 
predictor. Quality of studies ranged between 53% and 86% with an average value of 
67% (SD= 8.8%). ConClusions: Although adherence is a frequently studied topic, few 
studies consider personal traits as a forecasting factor of medication persistence. A 
new instrument considering Conscientiousness as behavior predictor is being devel-
oped, the CUMPLE-Q.
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PatIent-Centered reasons for PrImary non-adHerenCe as derIved 
from tHe Peer-revIewed LIterature
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objeCtives: Primary non-adherence (PNA) has been found to range from 1% 
to 57% with a mean and median of 16.4% and 15.0%, respectively. We abstracted 
patient-centered reasons for PNA and their prevalence from the peer-reviewed lit-
erature. Methods: A systematic review using PubMed was conducted. A backward 
search of each abstracted article was performed as well as a review of each abstracted 
article’s reference list. Patient-provided reasons for PNA were abstracted from each 
reviewed article Results: A total of 131 articles met search-term criteria, and 19 
contained patient-provided reasons for PNA. Eleven additional articles were identi-
fied from backward citation searches and/or review of the 19 article’s reference list 
for a total of 30 studies. Fifty unique reasons for PNA were abstracted. After qualita-
tive analysis, they were reduced to seven mutually-exclusive reasons. Prescription-
medication affordability was the most common reason for PNA (80% of studies), 
followed by lack of perceived need for the medication (67% of studies), perceived 
medication concerns (53% of studies), lack of perceived drug efficacy (33% of studies), 
forgetfulness (33% of studies), access barriers (33% of studies), and patient knowledge 
(27% of studies). ConClusions: PNA is common both. Few adherence interventions 
have been developed and evaluated for PNA. The first step in developing adherence 
interventions for PNA is to gain an understanding of patient-centered reasons for 
PNA. This review identified the seven foremost reasons for PNA from 30 published 
studies. These seven reasons were: prescription-medication affordability, lack of per-
ceived need for the medication, perceived medication concerns, lack of perceived drug 
efficacy, forgetfulness, access barriers, and patient knowledge. Researchers should 
standardize the content of PNA reasons to facilitate comparisons across patient sam-
ples. Many of the reasons for PNA can be addressed with patient-centered counselling 
at the time of prescribing. If we are to reduce PNA, doctor-patient communication 
must be improved to address patients beliefs about the need for the medication and 
their concerns about it.
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objeCtives: Adherence measurements developed for mono-pharmacotherapy, 
such as the Medication Possession Ratio (MPR), are not appropriate to calculate 
adherence to poly-pharmacotherapy. These standard metrics tend to over/under 
estimate adherence in patients with treatment regimens consist of multiple medi-
cations. This study aimed to develop a new method for calculating medication 
adherence in patients using poly-pharmacotherapy by linking prescribing and 
administration data of general practitioners (GPs), and pharmacy dispensing 
records. Methods: We evaluated existing methods for calculating medication 
adherence from dispensing data records. Standards for estimating medication 
adherence to poly-pharmacotherapy were defined. A new approach to calculate 
adherence to poly-pharmacotherapy was developed. Results: The proposed 
new approach for estimating medication adherence to poly-pharmacotherapy 
consists 2 novel indexes (the multiple-Medications Prescribing Ratio [mMPrR] and 
the multiple-Medications Possession Ratio [mMPR]) and a medication adherence 
visualization tool (the Prescription and Medication Possession Graph [PMPG]). The 
mMPrP is for calculating adherence to prescribe medications and the mMPR to (re)fill 
prescriptions. The PMPG completes the mMPrR and the mMPR with indicating medi-
cation adherence in time and allowing to evaluate tendencies in the observation 
period. Among other parameters, number of medications, therapeutic indication, 
treatment length (e.g., chronic conditions requiring periodic treatment), dosage, 
generic and therapeutic switching, therapeutic duplication, and oversupply were 
considered for the construction of mMPrP, mMPR and PMPG. The face-validity of 
the approach were demonstrated with four illustrative cases (i.e., generic switch-
ing, therapeutic duplication, oversupply, periodic treatment). ConClusions: The 
proposed new method enables a more accurate measurement of adherence to poly-
pharmacotherapy compared to MPR. The mMPrP, the mMPR and the PMPG would 
allow GPs to identify substantial adherence issues during consultations and could 
be routinely used to enhance medication adherence in countries where GPs have 
access to pharmacy dispensing records of their patients such as in Hungary.
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objeCtives: Self-care with non-steroidal anti-inflammatory drugs (NSAIDs), etc. 
is widely used for pelvic pain relief in dysmenorrhea patients in Japan; however, 
guideline-recommended medical intervention consists of low-dose estrogen and 
progestin hormonal combinations (LEP). This study aims to assess the cost-effec-
tiveness of intervention including LEP for the prevention of endometriosis and/or 
disease progression of dysmenorrhea, compared to self-care, in Japan. Methods: 
A Markov model with a 43-year time horizon and annual cycles was constructed. 
The model consisted of five major health states with four sub-medical states based 
on gynecologists’ consensus. The analyses were conducted from social, payer’s and 
woman’s perspectives. Transition probabilities among health and medical states were 
derived from epidemiological patient surveys. Disease-associated direct costs, such as 
inpatient, outpatient, surgery, and prescription and over-the-counter (OTC) drug costs 
were included. Utility measures were collected prospectively from patients with stage 
I-IV endometriosis using a visual analogue scale. An annual discount rate at 3% was 
considered. Sensitivity analyses were performed to examine the impact of uncertain-
ties. Results: Base case outcomes indicated that intervention would be superior to 
self-care when only considering direct costs (cost-saving amount of approximately 
240,000 JPY, with 4.4 incremental quality-adjusted life-years [QALYs] gained). From 
the payer’s perspective, intervention would be more cost-effective than self-care, as 
the incremental cost-effectiveness ratio (ICER) yielded 350,000 JPY per QALY gained. 
A tornado diagram depicting the deterministic sensitivity analysis was constructed, 
and robustness of the base case was confirmed. A probabilistic analysis resulting from 
10,000-time Monte Carlo simulations demonstrated efficiency at Willingness-To-Pay 
thresholds of 5,000,000 JPY in more than 90% of the population. ConClusions: Our 
analysis demonstrated that, in Japan, intervention would be more cost-effective than 
self-care in preventing endometriosis and/or disease progression for patients with 
dysmenorrhea. These findings could be used to inform health-care decision-making 
in women with dysmenorrhea and health-policy makers.
IndIvIduaL’s HeaLtH – Patient-reported outcomes & Patient Preference  
studies
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objeCtives: This study reviews adherence metrics for Phase IV studies. Methods: 
We conducted a review of adherence metrics in the public domain. We critically 
appraised these metrics for use in Phase IV studies. Results: We identified 70 
unique self-report measures of adherence. One quarter (26%) were generic and the 
remaining were disease specific. Instrument length ranged from one to 78 items. 
One third (34%) only measured adherence behaviors, 37% only measured beliefs and 
attitudes, and 29% measured both. Just over one quarter (29%) were developed using 
a conceptual framework. One-fifth (21%) involved qualitative patient input during 
item generation or pretesting. Just over one-half (57%) had evidence of internal-
consistency reliability, and far fewer had evidence of test-retest reliability (23%). 
One half (50%) had evidence of validity vis á vis other self-report measures, 23% vis 
á vis other adherence metrics, and 19% vis á vis clinical criteria. Few had evidence 
of predictive (24%) or postdictive (13%) validity. ConClusions: Few adherence 
measures have been developed with true patient-centerednesss. There has been no 
standardization of the content of adherence behaviors or beliefs. Instrument vali-
dation has been inconsistent in its breadth and depth. Because of the importance 
of medication adherence to payers, providers, pharmacies, and pharmaceutical 
companies, the time seems opportune to conceptualize, develop, and validate a 
generic adherence measure that can be used in Phase IV studies across different 
disease and patient groups. Standardization of content would allow for the assess-
ment of adherence behaviors and beliefs between and across existing and novel 
therapies. There should be a minimum set of adherence concepts that apply across 
therapeutic areas. The new measure should be developed with patient input (con-
cept elicitation) and verified as to its comprehension and relevance using cognitive 
debriefing. The scientific basis of medication adherence would be advanced through 
the development and validation of a standardized generic measure that assesses 
adherence behaviors and beliefs.
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objeCtives: A systematic review of scientific articles was accomplished in order to 
identify personal factors used as predictors of adherence to medication. Methods: 
PubMed, PsycINFO, and cross-references were consulted using standardized queries. 
Original works were summarized using a pre-stablished set of content indicators. A 
multi-criteria decision analysis tool was developed to assess research quality, using 
12 independent criteria: Explicative model, adherence measure, predictive validity, 
pathologies studied, concurrent validity, structural validity, construct validity, dis-
criminant validity, sample size, study type, theoretical framework, and bibliographic 
review. Each criteria was valued as very good (100), good (80), acceptable (60), and 
bad (0/20); and a weighted sum was obtained considering all criteria. Valuations 
were carried out by two independent researchers and lack of agreement was dis-
entangled by a third reviewer. Results: A total of 113,560 studies were identified 
related to “adherence” and “persistence” between 1980 (454 studies) and May 2015, 
exhibiting an exponential growth rate with a maximum of 8,744 studies in 2014. 
After refining our search for personal predictive factors we ended with 272 articles 
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dialogues between manufacturers and HTA bodies to generate robust utility data. 
Economic evaluation of pharmaceuticals in France will follow a learning curve for 
both the manufacturers and for HAS.
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(ComParIson of dIfferent metHods and wItH generaL PoPuLatIon)
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objeCtives: Since 2010, there has been established a Polish EQ-5D value set using 
the time trade-off (TTO) method. Pharmacy students gain a professional knowledge 
on health problems and treatment during their education. The aim of this study 
was to assess how do medical students value health on the EQ-5D compared with 
the general population and with the use of different methods of direct measure-
ment of preferences. Methods: 135 students of the 5th year of pharmacy of the 
Wroclaw Medical University took part in the face to face interview. Students were 
asked to assess randomly selected 5 out 243 hypothetical EQ-5D-3L health states. 
Visual analogue scale (VAS), TTO and standard gamble (SG) were used. Responses 
indicating the misunderstanding of the task have been removed. Results: We 
obtained 664 useable valuations. No health state has been valued as worse than 
death. Appropriate additive models have been built: for VAS (with all coefficients 
statistically significant, R2 equal to 0.488, and the worst possible health state valued 
as 0.089), for TTO (with all coefficients statistically significant except for constant 
and UA2, R2 equal to 0.292, and the worst possible health state valued as 0.540) and 
for SG (with all coefficients statistically significant except for constant and AD2, R2 
equal to 0.196, and the worst possible health state valued as 0.582). With the use 
of TTO, almost all health states were valuated higher by the pharmacy students 
compared to data of the general population ConClusions: Pharmacy students 
have a tendency to value health states higher than the general population. The 
valuation highly depends on the method used.
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objeCtives: To develop a set of weights for EQ-5D-3L health states based on the val-
ues of a representative sample of the Hungarian population. Methods: A national 
population survey (n= 5,503) containing self-reported health status were analysed to 
identify respondent’s EQ-5D-3L health state. The survey also included a visual ana-
logue scale (VAS) rating of the respondent’s health on a 0-100 scale. Mean VAS rating 
for each observed EQ-5D-3L state were computed, yielding an average value for each 
“naturally” occurring EQ-5D health states. OLS regression yielded a well-behaved set 
of coefficients representing the value loss for each problem level/dimension. This 
estimation model was then applied to create a value set for all 243 EQ-5D-3L health 
states. Results: The most frequently reported health state was 11111 (48.6%) with 
a mean VAS rating of 82.5. The worst health state was rated at 25.4, represent-
ing a somewhat compressed range of values. Logically consistent coefficients for 
all 5 dimensions revealed largest value losses for Pain/Discomfort and Anxiety/
Depression level#3. Self-care level#2 produced the smallest value loss. Values for all 
243 health states were estimated using the derived value loss function. The value 
for dead generated in the European BIOMED was used to transform these estimated 
values onto a 0-1 format suitable for use in QALY calculations. ConClusions: In 
common with other countries, many Hungarian analysts use the UK MVH value 
set as a stop-gap. This expedient provides a means of satisfying the requirements 
for QALY calculations but risks compromising the principle that social decision-
maker should use values of the relevant population. Substitution of UK values may 
be empirically unsound. An alternative value set for EQ-5D-3L based on data from 
national Hungarian sources is now available, providing a robust counter-factual 
for comparative analysis.
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objeCtives: To evaluate health state utility values in mild and severe primary 
dysmenorrhea (PD) in patients and controls. Methods: A convenience sample 
of female university students and staff was invited to participate in a web-based 
survey. Inclusion criteria to the study were: i) aged 18 to 40 years; ii) nulliparous 
and not pregnant at the time of the survey; iii) having menstrual periods; and iv) no 
pelvic pathology. Subjects reporting a history of menstrual cramps with an onset of 
> 20 years of age were excluded. Participants with pain intensity of > 3 on an 11-point 
numeric rating scale were classified as patients, whereas those without history of 
menstrual cramps or with pain intensity of ≤ 3 were considered as controls. The 
10-year time trade-off was applied to assess utilities for two hypothetical PD health 
states characterised by menstrual cramps and associated symptoms. Results: 
Altogether 556 adults were completed the questionnaire with mean age of 23±3.5 
years. Of these, 399 (72%) reported symptoms of PD and 157 (28%) were grouped as 
controls. Overall 19%, 49% and 32% had mild, moderate or severe PD based on the 
verbal multidimensional scoring system for assessment of dysmenorrhea severity. 
Mean utilities for the mild and severe hypothetical health states were 0.97±0.14 and 
0.88±0.24, p< 0.001. Compared to the control group, PD patients attached significantly 
lower utilities to the mild health state (0.96 vs. 0.99, p= 0.011) but not to the severe 
(0.86 vs. 0.90, p= 0.420). ConClusions: This study provides the first utility values 
in PD. Disutility experienced in PD – ranging between 0.01 and 0.14 depending on 
severity and the group who valued them – is definitely not negligible. Severe PD 
may have a similar impact on utilities as living with chronic migraine. Utilities 
evaluated in this study can be used as inputs for cost-effectiveness analyses of 
health interventions.
objeCtives: Time tradeoff (TTO) values of the EQ-5D-5L health states measured 
in China’s EQ-VT study varied across sampled locations. This might be a sign of 
different health preferences in those locations, or it might be a sign of salient inter-
viewer effects or respondent’s differing understanding of the TTO task. Task under-
standing could be assessed in terms of individual-level inconsistency in valuation. 
Relating inconsistency to the characteristics of the respondent, interviewer, and 
interview can therefore help to understand the variations in values. Methods: 20 
Interviewers interviewed 1,296 respondents and each respondent valued 10 health 
states using the EQ-VT (TTO) protocol in 5 cities in China. At the respondent level, 
inconsistency in valuation was assessed in terms of severity and quantity and was 
then related to respondent’s background characteristics, interviewer identity, and 
performance of TTO tasks and the data that related to the ‘wheelchair example’ 
which is used to train the respondent. An Ordered logistic regression were used for 
statistical analysis. Results: In the full dataset, no relation between respondent’s 
education and inconsistency was found, nor did a relation between location and 
inconsistency exist. However, we did find a positive association between time spent 
on TTO tasks and inconsistency and a negative association between time spent on 
the wheelchair example and inconsistency. In addition, respondents interviewed 
by one particular interviewer were found to be highly inconsistent. After excluding 
the data collected by this interviewer, the remaining 19 interviewers were similar in 
the inconsistency level, and the relation between interview process and inconsist-
ency was stronger. ConClusions: Inconsistency strongly related to interviewer 
and then to interview process, but has limited association with respondents’ back-
ground variables. This result, in turn, suggests that the variance in values between 
locations is not due to differences in understanding the task, but possibly due to 
different health preferences.
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objeCtives: The purpose of this study was to measure the population norms for 
the Japanese versions of preference-based measures (EQ-5D-3L, EQ-5D-5L and 
SF-6D). We also considered the relations between QOL score in the general popu-
lation and socio-demographic factors. Methods: Data in this study came from 
Ministry of Health, Labour and Welfare (MHLW) survey, which took a representa-
tive sample. A total of 1,143 adult respondents (aged ≥ 20 years) were randomly 
sampled from across Japan using data from the Basic Resident Register. The health 
status of each respondent was measured using the EQ-5D-3L, EQ-5D-5L, and SF-6D, 
and responses regarding socio-demographic data as well as subjective diseases 
and symptoms were obtained. The responses were converted to a QOL score using 
Japanese value sets. Results: The percentages of respondents with full health 
scores were 68% (EQ-5D-3L), 55% (EQ-5D-5L), and 4% (SF-6D). The QOL score meas-
ured using the SF-6D was significantly lower than those measured using either 
EQ-5D score. The QOL score was significantly lower among respondents over the 
age of 60 years, those who had a lower income, and those who had a shorter period 
of education. Intraclass correlation coefficient (ICC) showed a poor agreement 
between the EQ-5D and SF-6D scores. The differences in QOL scores between 
respondents with and those without any disease were 0.064 for the EQ-5D-3L, 
0.061 for the EQ-5D-5L, and 0.073 for the SF-6D; these differences are regarded as 
minimal important differences (MID) in the general population. ConClusions: 
The Japanese population norms of three preference-based QOL measures were 
examined for the first time. Such information is useful for economic evaluations 
and research examining QOL score.
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objeCtives: Economic evaluation of pharmaceuticals and medical devices has 
been introduced in France in October 2013. Economic evaluations by HAS are 
based on critical appraisals of manufacturers’ submissions. We reviewed the selec-
tion and use of health utility values for cost-utility analyses (CUA) submitted to 
HAS. Methods: A review of manufacturers’ CUA submitted to and assessed by 
HAS by end of May 2015 was undertaken to review the identification and selection 
of data and the methods used for deriving utility estimates. The methods used 
were compared with those recommended in the HAS methodological guideline on 
economic evaluation. Results: Of the 27 submissions, 16 (56%) included utility 
values from previously published studies, only 4 of which reported a systematic 
literature review; 10 (37%) from the clinical trials informing the clinical effec-
tiveness; 2 (7%) from a mixture of sources. To describe health states, 21 (78%) 
submissions used a preference-based generic instrument, mostly the EQ-5D; 5 
(19%) used vignettes; 3 used a condition-specific instrument. Several submis-
sions used different types of instrument. In most (85%) submissions, the valua-
tion method was the time-trade off. The valuation perspective was the general 
population in 23 (85%) submissions; in only 5 (19%) submissions, the valuation 
set was derived from the French general population. In 14 (52%) submissions, 
further adjustments to utility values were made, mostly to account for adverse 
events. ConClusions: We identified numerous concerns in the selection, valu-
ation and use of utility values, and a frequent lack of clarity in the description of 
the methods used. Many submissions included utility values that did not meet the 
HAS reference case for economic evaluation. There is a need to strengthen early 
